Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT102 in advanced pancreatic cancer
NCT06760364Phase 1Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHT102 in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Safety and Tolerability at 2 years. Started Dec 2024; status: recruiting.
02
Drugs
CHT102
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06760364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760364.